An 11-amino-acid peptide derived from erythropoietin, engineered to drop the blood-building effect and keep only the tissue-protective signal. People run it for nerve pain, small-fiber neuropathy, and quieting inflammation, often alongside BPC-157.
Prices from 5 vendors across the market. We link straight to each vendor’s product page and grade vendors on public lab data, so you’re not just chasing the lowest number.
The simple version first, then a little more for the curious. No biochem degree required.
It flips on the body's innate repair switch, a receptor that wakes up in injured tissue, so nerves and blood vessels can calm down and repair without the blood-thickening effect of EPO.
ARA-290 (cibinetide) is a synthetic fragment of erythropoietin's tissue-protective region. It targets the innate repair receptor, a complex of the EPO receptor and the beta-common receptor that only assembles in injured or stressed tissue, so it acts where there is damage.
It is studied for small nerve fibers, the vascular lining, and inflamed tissue. Because the receptor appears mainly at sites of injury, the signal is aimed at damaged areas rather than acting like a general systemic hormone.
In sarcoidosis nerve-pain trials, people reported less neuropathic pain and showed regrowth of small nerve fibers over weeks. Outside those trials, reports center on nerve discomfort and inflammation rather than fast, dramatic change.
Honest caveat: ARA-290 has real human trial data in sarcoidosis small-fiber neuropathy, which is more than many peptides can claim, but those trials were small and it never reached approval. It is not an approved medicine and is sold strictly for research use only. None of this is medical advice, talk to a licensed provider before starting anything.
ARA-290 is an injection, given subcutaneously into fat with a tiny insulin needle. It isn't an oral peptide, so the injectable form is what people run. The routine is below; for cycling and timing, see the full guide.
Add bacteriostatic water down the side of the vial (a 10mg vial + 2mL = 5mg/mL). Let it dissolve. Swirl gently, don't shake.
On a U-100 insulin syringe, pull to your unit mark. 4mg at 5mg/mL is 80 units (0.8mL). Use the calculator if you're unsure.
Swab with alcohol, pinch a bit of fat, insert at 45–90°, push slowly. Subcutaneous into the belly is the standard route used in the clinical trials.
Move to a different spot each time so no area gets sore or lumpy. Store the vial in the fridge between doses.
The easiest spots are the belly (about 2 inches either side of the navel), the love handles, the front of the thigh, and the back of the upper arms. Rotate every injection.
This is ARA-290's typical setup, already worked out. Change any value and the draw updates instantly.
Typical ARA-290 dose: about 4 mg once daily, the dose used in the sarcoidosis trials, run for roughly 4 weeks at a time. It's run in focused cycles, not continuously.
How long people run ARA-290, when to take a break, and the honest reasoning behind it.
Run in focused courses.
A cycle just means a defined run of time on the peptide, followed by a break. For ARA-290 the common pattern follows the trials: roughly four weeks of daily dosing, then time off, rather than running it indefinitely.
Why not just run it forever? Mostly because the long-term human safety data does not exist yet. The trials lasted weeks to a few months, not years, so the cautious approach is a focused block, then stop.
Want the full picture, on and off periods, the washout, stacking, and keeping your results? Read how peptide cycling works →
For one of these vendors we link the per-batch certificate itself, and the purity below is read straight off it. The rest link to the vendor's general lab-results page. We don't run the labs ourselves and we don't show a purity number unless it's printed on a certificate we link, so you can open the document and check it against the batch yourself.
| Vendor | Purity (per COA) | Batch / report | Certificate |
|---|---|---|---|
| EZ Peptides | 99.827% | EZP-ARA1005192026-03 | Janoshik report ↗ |
| Penguin Peptides | see lab page | not shown | Lab results ↗ |
ARA-290 is often paired for nerve and tissue repair. These are the combinations the community reaches for.
The repair-focused pair people run for nerve pain. ARA-290 works on the innate repair receptor and small nerve fibers; BPC-157 adds local soft-tissue and gut support. Different mechanisms aimed at the same recovery goal.
View stack →ARA-290 quiets inflammation through the innate repair receptor, while TB-500 is run for whole-body recovery and mobility. People reach for this when both nerve discomfort and soft-tissue recovery are in play.
View stack →ARA-290 for the nerve and inflammation angle, DSIP for the sleep-and-recovery side. Some people pair them when poor sleep is part of the picture, though the DSIP evidence is thin.
View stack →Other healing and recovery peptides people compare against ARA-290.
ARA-290 isn't an approved drug, and it isn't sold for human use. The vendors we compare offer it strictly for research use only. It holds FDA orphan-drug status for sarcoidosis nerve pain but never reached approval. Rules vary by country, so check what applies where you are.
It means the product is sold for laboratory and research purposes, not as a supplement or medicine for people. It hasn't been reviewed or approved for human use by the FDA. We aggregate prices and public lab data so you can see the landscape; what you do with that is between you and a licensed provider.
Keep the sealed, freeze-dried vial in the fridge, and out of direct light. Once you mix it with bacteriostatic water, store it refrigerated and use it within a few weeks. Don't freeze a reconstituted vial.
The clinical trials used 4 mg once daily for about four weeks. People tend to copy that, running a focused daily block rather than dosing indefinitely. Use the calculator to turn your vial and dose into exact units.
No. ARA-290 is built from the tissue-protective region of erythropoietin but was deliberately engineered to drop the blood-building effect. It does not raise red blood cell count the way EPO does; it targets the innate repair receptor instead.
This site is for educational and informational purposes only and is not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and none of these statements have been evaluated by the FDA or any regulatory authority. Talk to a licensed healthcare provider before starting anything.
Peptides and other compounds referenced on this site are sold by third-party vendors strictly as research chemicals for laboratory and research use only. They are not drugs, dietary supplements, cosmetics, or products intended to diagnose, treat, cure, or be consumed by humans or animals, and nothing here is an offer to sell or any encouragement to use them in any such way. You must be at least 18 years old, and of legal age in your jurisdiction, to use this site. Clearly Peptides does not manufacture, sell, supply, or ship any peptides or compounds.
Lab data, grades, and prices are aggregated from publicly available third-party sources, primarily the Janoshik public database and finnrick, plus community-submitted reports. We don't run labs or test anything ourselves. We present this public information, credit each source, and link back to the original report so you can read it yourself. Listing a vendor or compound is not an endorsement.
Clearly Peptides participates in affiliate programs and may earn a commission when you buy through a link or code on this site, at no extra cost to you.
Clearly Peptides is not liable for any actions you take based on the information provided here. Your use of this site is subject to our Terms of Use.